Search
Oplunofusp
go.drugbank.com/drugs/DB15313InvestigationalDAS-181 is under investigation in clinical trial NCT00527865 (Single Dose Escalating Study of DAS181 in Adults).
IFx-Hu2.0
go.drugbank.com/drugs/DB18396InvestigationalIt is composed of plasmid DNA encoding the streptococcal membrane protein, Emm55, contained within a cationic polymer.
Synonyms: Immunotherapeutic vaccine consisting of pAc/emm55, a plasmid DNA (pDNA), which codes for a modified immunogenic, streptococcal Emm55 protein, complexed with in vivo-jetPEI® polymer-based reagent linearAG0302-COVID19
go.drugbank.com/drugs/DB16435InvestigationalSponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].
Revefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigationalThe LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD … [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]
Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigationalIxazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor. … [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexMetrizoic acid
go.drugbank.com/drugs/DB09346ApprovedMetrizoic acid is a molecule used as a contrast medium. It present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA. … A total of 10, 000 injections were administered to 2,028 patients undergoing angiocardiographic procedures over a three-year period.
Categories: Compounds used in a research, industrial, or household settingOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.
Baxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalOn May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … It targets aldosterone excess, a primary underlying driver of treatment resistance and organ damage in cardiovascular diseases [A275512, A275515].
Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … [A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme
Methylcellulose
go.drugbank.com/drugs/DB11228ApprovedInvestigationalThe Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum of 3, however more typical values … Methyl cellulose is a hydrophilic white powder in pure form and dissolves in cold (but not in hot) water, forming a clear viscous solution or gel.
Categories: Compounds used in a research, industrial, or household setting